Amneal Pharmaceuticals, Inc. - News - Press Releases

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002

Dec 20, 2022

Amneal Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval

Nov 23, 2022

Amneal to Participate at Upcoming Investor Conferences

Nov 22, 2022

Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States

Nov 11, 2022

Amneal Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease

Nov 04, 2022

Amneal Reports Third Quarter 2022 Financial Results

Nov 02, 2022

Amneal Receives FDA Approval for Leuprolide Acetate Injection

Oct 31, 2022

Amneal Expands Leadership Team with Appointment of Senior Leaders in Quality and Regulatory

Oct 06, 2022

Amneal to Report Third Quarter 2022 Results on November 4, 2022

Oct 03, 2022

Amneal Launches First Biosimilar with ALYMSYS® (bevacizumab-maly) in the United States

Sep 06, 2022

Amneal Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer – Specialty

Aug 31, 2022

Amneal Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease

Aug 22, 2022

Amneal supports Congress’ efforts to ensure essential medicines are Made in America

Aug 11, 2022

Amneal launches 4 new Generic products, including Vasopressin single-dose

Aug 05, 2022

Amneal Reports Second Quarter 2022 Financial Results

Aug 03, 2022

Amneal Appoints Deborah M. Autor to Board of Directors

Jul 08, 2022

Amneal to Report Second Quarter 2022 Results on August 5, 2022

Jun 07, 2022

Amneal Releases 2021 Corporate Responsibility Report Highlighting Continued ESG Impact and Integration

Jun 01, 2022

Amneal Launches LYVISPAH® (baclofen) for Spasticity Related to Multiple Sclerosis and Other Spinal Cord Disorders

May 27, 2022

Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk)

May 24, 2022

Amneal to Participate at the 2022 Jefferies Healthcare Conference

May 13, 2022

Amneal to Participate at Upcoming Investor Conferences in May

May 04, 2022

Amneal Reports First Quarter 2022 Financial Results

Apr 13, 2022

Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)

Apr 07, 2022

Amneal to Report First Quarter 2022 Results on May 4, 2022

Mar 24, 2022

Amneal to Present Results From the Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 at the 2022 American Academy of Neurology Annual Meeting

Mar 17, 2022

Amneal Awarded Sub-License to Manufacture and Commercialize Generic Version of Co-Packaged Nirmatrelvir and Ritonavir in 95 Low- and Middle-Income Countries

Mar 02, 2022

Amneal Reports Fourth Quarter and Full Year 2021 Financial Results

Mar 01, 2022

Amneal Enters U.S. Biosimilars Market With Approval of RELEUKO^® (filgrastim-ayow)

Feb 17, 2022

Amneal Expands Injectables Portfolio with 4 New Products

Feb 04, 2022

Amneal to Report Fourth Quarter and Full Year 2021 Results on March 2, 2022

Jan 05, 2022

Amneal Acquires Saol Therapeutics’ Baclofen Franchise

© Amneal Pharmaceuticals LLC.

All rights reserved.

Powered By Q4 Inc. 5.96.0.15